Semi-Annual Consolidated Statement Of Cash Flows

Carna Biosciences, Inc. - Filing #7272198

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
-1,367,545,000 JPY
-1,640,892,000 JPY
Interest paid
-2,841,000 JPY
-3,365,000 JPY
Net cash provided by (used in) operating activities
-1,374,806,000 JPY
-1,677,464,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-13,060,000 JPY
-11,530,000 JPY
Other, net
JPY
154,000 JPY
Net cash provided by (used in) investing activities
-13,060,000 JPY
-11,376,000 JPY
Cash flows from financing activities
Redemption of bonds
JPY
-32,032,000 JPY
Repayments of long-term borrowings
-120,000,000 JPY
-119,988,000 JPY
Net cash provided by (used in) financing activities
567,441,000 JPY
1,182,027,000 JPY
Other, net
-7,557,000 JPY
-9,290,000 JPY
Effect of exchange rate change on cash and cash equivalents
39,809,000 JPY
16,865,000 JPY
Net increase (decrease) in cash and cash equivalents
-780,616,000 JPY
-489,947,000 JPY
Cash and cash equivalents
2,108,484,000 JPY
2,889,101,000 JPY
3,379,048,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.